BIOCARDIA INC (BCDA) Stock Price, Quote, News and Overview
NASDAQ:BCDA - Nasdaq - US09060U6064 - Common Stock - Currency: USD
BCDA Quote, Performance and Key Statistics
2.3
+0.12 (+5.5%)
The current stock price of BCDA is 2.3 USD. In the past month the price decreased by -5.74%. In the past year, price decreased by -23.33%.
BCDA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.58 | 337.14B | ||
| AMGN | AMGEN INC | 14.24 | 158.93B | ||
| GILD | GILEAD SCIENCES INC | 14.32 | 137.86B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 115.79B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.8 | 56.43B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.26B | ||
| ARGX | ARGENX SE - ADR | 95.86 | 33.66B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.76 | 28.60B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.56B | ||
| NTRA | NATERA INC | N/A | 22.97B | ||
| BIIB | BIOGEN INC | 8.28 | 19.20B | ||
| INSM | INSMED INC | N/A | 18.50B |
Related stock screener links
About BCDA
Company Profile
BioCardia, Inc. is a clinical-stage biotherapeutic company. The company is headquartered in Sunnyvale, California and currently employs 17 full-time employees. The company is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
Company Info
BIOCARDIA INC
320 Soquel Way
Sunnyvale CALIFORNIA 94070 US
CEO: Peter Altman
Employees: 19
Phone: 16502260123
BIOCARDIA INC / BCDA FAQ
What is the stock price of BIOCARDIA INC today?
The current stock price of BCDA is 2.3 USD. The price increased by 5.5% in the last trading session.
What is the ticker symbol for BIOCARDIA INC stock?
The exchange symbol of BIOCARDIA INC is BCDA and it is listed on the Nasdaq exchange.
On which exchange is BCDA stock listed?
BCDA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIOCARDIA INC stock?
8 analysts have analysed BCDA and the average price target is 15.81 USD. This implies a price increase of 587.39% is expected in the next year compared to the current price of 2.3. Check the BIOCARDIA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIOCARDIA INC worth?
BIOCARDIA INC (BCDA) has a market capitalization of 11.91M USD. This makes BCDA a Nano Cap stock.
How many employees does BIOCARDIA INC have?
BIOCARDIA INC (BCDA) currently has 19 employees.
What are the support and resistance levels for BIOCARDIA INC (BCDA) stock?
BIOCARDIA INC (BCDA) has a support level at 2.28 and a resistance level at 2.31. Check the full technical report for a detailed analysis of BCDA support and resistance levels.
Is BIOCARDIA INC (BCDA) expected to grow?
The Revenue of BIOCARDIA INC (BCDA) is expected to decline by -100% in the next year. Check the estimates tab for more information on the BCDA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIOCARDIA INC (BCDA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BCDA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BCDA, evaluating the profitability, health, valuation and growth aspects
- BIOCARDIA INC (BCDA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIOCARDIA INC (BCDA) Sales and EPS estimates to see what analysts future expectations are.
- BIOCARDIA INC (BCDA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIOCARDIA INC (BCDA) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIOCARDIA INC (BCDA) Stock Chart to make your own analysis
- BIOCARDIA INC (BCDA) Latest news and press-releases to stay up to date.
Does BIOCARDIA INC (BCDA) stock pay dividends?
BCDA does not pay a dividend.
When does BIOCARDIA INC (BCDA) report earnings?
BIOCARDIA INC (BCDA) will report earnings on 2025-08-11.
What is the Price/Earnings (PE) ratio of BIOCARDIA INC (BCDA)?
BIOCARDIA INC (BCDA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.58).
What is the Short Interest ratio of BIOCARDIA INC (BCDA) stock?
The outstanding short interest for BIOCARDIA INC (BCDA) is 1.7% of its float. Check the ownership tab for more information on the BCDA short interest.
BCDA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BCDA. When comparing the yearly performance of all stocks, BCDA is a bad performer in the overall market: 84.95% of all stocks are doing better.
BCDA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BCDA. BCDA has a bad profitability rating. Also its financial health evaluation is rather negative.
BCDA Financial Highlights
Over the last trailing twelve months BCDA reported a non-GAAP Earnings per Share(EPS) of -2.58. The EPS increased by 14.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -387.4% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BCDA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to BCDA. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 67.85% and a revenue growth -100% for BCDA